The know-how that marked a turning level within the Coronavirus pandemic, the messenger RNA, continues to beat territories within the vaccination ecosystem. A brand new analysis, revealed on Wednesday within the journal Jamahas underpinned the trail to optimize vaccination in opposition to two giant respiratory viruses: the influenzavirus of the flu and the Sars-Cov-2 of the COVID. The essay, developed by the fashionable pharmacist, has discovered that its mixed vaccine achieves an immune response akin to that of different particular person preparations already approved in opposition to these infections. Although this examine doesn’t measure the effectiveness of the remedy and would require extra analysis to research this elementary aspect, researchers recommend that the event of a single vaccine in opposition to these two illnesses may help enhance vaccination protection.
The flu and Covid virus are already previous acquaintances in public well being, however their influence continues to verify the well being programs and lifetime of tens of millions of individuals yearly: it’s estimated that, yearly, on the earth, about one billion instances of flu and a couple of.3 billion covid are recorded; Already regardless of its virulence, particularly in folks over 65, vaccination in opposition to these microorganisms stays, within the eyes of scientists, “suboptima.” In Spain, the vaccination protection for the flu among the many most susceptible teams for its age is 67%; And for Covid, 35%.
The World Health Organization (WHO) recommends, in actual fact, the joint administration of vaccines in opposition to these two viruses to enhance protection, however the authors of this analysis argue {that a} multicomponent vaccine – that’s, mixed – “can be a preferable option to vaccinate against both diseases in a single injection.” Researchers hypothesize that this technique may enhance compliance with immunization tips and, “ultimately, mitigate the disease.” Time will say if these expectations are met, however their experimental vaccine, for now, is already within the advance of this therapeutic technique.
The provisional knowledge of a section 3 trial with its messenger RNA preparation, which is directed in opposition to 4 flu strains and one of many SARS-COV-2, exhibits that, in folks over 50, a single dose of its vaccine achieves a response of the immune system akin to that of different preparations already approved by the regulatory businesses. In the examine, the comparability is with two conventional tetravalent vaccines in opposition to the flu and one other – fashionable and likewise of messenger RNA – for the Covid. “The RNM-1083 [el nombre con el que se conoce el nuevo preparado de Moderna] It induced higher immune responses against the three strains of clinically relevant influenzavirus and the SARS-COV-2 that authorized comparison vaccines evaluated in this trial, ”clarify the authors. It additionally introduced some ranges of tolerance and security just like these of the vaccines with which it was in contrast.
The article additionally highlights the advantages of the Messenger RNA platform when designing or modifying the vaccine in opposition to these two viruses. For instance, “rapid production and flexibility to update the vaccine composition can guarantee close correspondence with circulating strains” of those viruses, they level out.
This is just not the one novel experiment in progress to fight two respiratory viruses with pandemic potential. The epidemiologist Toni Trilla remembers that there are related vaccines below examine by Pfizer-Bionntec and GSK-Curevac, however in earlier phases of analysis. Also with Messenger RNA know-how, there are lively research searching for, for instance, of a common vaccine in opposition to the flu virus, an particularly advanced microorganism for its huge mutation capability and since you by no means know with certainty what pressure will flow into in every season. And past the messenger RNA, the European Medication Agency (EMA) has additionally permitted a sort of prepaides vaccine, a serum in opposition to avian flu that, if a disaster happens by this pathogen, can be able to be manufactured.
Caution amongst specialists
Regarding the analysis revealed in JamaAmós García Rojas, former president of the Spanish Society of Vaccination, factors out that it’s “a novel project as it encompasses two vaccines that had to be given separately, but it is not the only line of research that is in relation to combined vaccines of flu and covid,” he impacts. On the outcomes, it’s prudent: “The protective and safety response data for both flu and Covid are positive. In principle, it is a study that allows us to have hope in this combined vaccine, but we will see how the subject continues to evolve.”
In the identical line of warning, Trilla considers the investigation “a step forward”, however slides that there are nonetheless “many variables to consider to be able to argue for or against the possible future employment of this type of messenger vaccines combined for flu and covid.” The epidemiologist remembers that, though a vaccine of this sort is “easier to manufacture, more quickly adaptable to changes in the predominant strains of both viruses and easier to administer”, additionally “it’s in all probability rather more costly. Better a puncture than two, however the worth is usually a deterrence: the standard flu vaccine is less expensive Choose flu).
https://elpais.com/salud-y-bienestar/2025-05-07/un-pinchazo-doble-escudo-exito-preliminar-de-una-vacuna-conjunta-frente-a-covid-y-gripe-en-mayores-de-50.html